A rare genetic condition leads to developmental difficulties, happy disposition. Oct. 22, 2008— -- Six-year-old Ryan Ravellette is a happy and sociable child; he has a smile that can light up a ...

Affected populations: The disorder is believed to affect somewhere between 1 in 12,000 and 1 in 24,000 people, although these figures may be underestimated. Many cases of Angelman syndrome can go ...

Actor Colin Farrell has opened up about the difficult decision to move his son James, who has Angelman syndrome, into a long-term care facility. In an interview this week the actor, 48, revealed he ...

Angelman syndrome is a rare neurodevelopmental disorder arising primarily from loss of function of the maternally inherited UBE3A gene. Research has shown that UBE3A plays a crucial role in neuronal ...

Cincinnati native Charlie Nuck has a 6-year-old niece named Briar. She has a rare, neurogenetic disorder called Angelman syndrome. It affects about one in 15,000 people and causes developmental delays ...

Colin Farrell has opened up on his difficult decision to place his disabled son in long-term care. James was born to Colin and ex-partner US model Kim Bordenave. The youngster was diagnosed with the ...

Kathryn Ely remembers every detail from the process of her son being diagnosed with Angelman Syndrome, a rare genetic disorder that causes developmental delays, intellectual disabilities, seizures and ...

NISSWA — Two bicyclists are embarking on a 4,200-mile trip across the country for a deeply personal cause. Known as “Bike 4 Briar,” the team includes Todd Downey and Charlie Nuck, who seek to raise ...

3-year-old Bellamy Bresaw of Bow was diagnosed with Angelman Syndrome at nine months old. Credit: Delores Flanders / Courtesy Delores Flanders and her family are hosting a fundraiser at Boutwell’s ...

MIDDLETON, Mass., Sept. 22, 2025 /PRNewswire/ -- MavriX Bio, a clinical-stage biotechnology company focused on the development of transformative genetic therapies for Angelman syndrome (AS), today ...

Company expects to complete Phase 3 Aspire study in the second half of 2026 Aurora study of GTX-102 in additional ages and genotypes on track to initiate in the second half of 2025 NOVATO, Calif., ...